Literature DB >> 16079890

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

E Antonioli, P Guglielmelli, A Pancrazzi, C Bogani, M Verrucci, V Ponziani, G Longo, A Bosi, A M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16079890     DOI： 10.1038/sj.leu.2403902

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  36 in total

1.  Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.

Authors:  Mutlu Karkucak; Tahsin Yakut; Vildan Ozkocaman; Fahir Ozkalemkas; Ridvan Ali; Murat Bayram; Orhan Gorukmez; Gokhan Ocakoglu
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

2.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

Authors:  Ross L Levine; Claude Belisle; Martha Wadleigh; David Zahrieh; Stephanie Lee; Pierre Chagnon; D Gary Gilliland; Lambert Busque
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

3.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Jerry L Spivak
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

Review 4.  X-linked clonality testing: interpretation and limitations.

Authors:  George L Chen; Josef T Prchal
Journal:  Blood       Date:  2007-04-13       Impact factor: 22.113

Review 5.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

6.  2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.

Authors:  Jan Jacques Michiels; Mihaela Tevet; Adrian Trifa; Emilia Niculescu-Mizil; Anca Lupu; Ana Maria Vladareanu; Horia Bumbea; Anca Ilea; Camelia Dobrea; Daniela Georgescu; Oana Patrinoiu; Mihaela Popescu; Meilin Murat; Cornel Dragan; Felicia Mihai; Sabina Zurac; Silvana Angelescu; Anamaria Iova; Alina Popa; Rodica Gogulescu; Violeta Popov
Journal:  Maedica (Bucur)       Date:  2016-03

7.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

8.  A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide.

Authors:  Barbara Denys; Hakim El Housni; Friedel Nollet; Bruno Verhasselt; Jan Philippé
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.568

Review 9.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

10.  A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

Authors:  Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  J Mol Diagn       Date:  2008-07-31       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.